



Hepatitis B Vaccination for Adults

Published: June 2025

	Vaccine Name	Patient Population & Approved Dose Volume	Number of Doses and Timing	Route of Administration
Single-antigen Hepatitis B Vaccines	Engerix-B® [Hepatitis B Vaccine (Recombinant)]	Adults 20 years and older: 1 mL	3 doses at 0, 1, and 6 months	Intramuscular
		Adults on hemodialysis or with immunocompromising conditions: 2 mL	4 doses at 0, 1, 2 and 6 months	Intramuscular
	Recombivax HB® [Hepatitis B Vaccine (Recombinant)]	Adults 20 years and older: 1 mL	Product: Recombivax HB® Adult Formulation 3 doses at 0, 1, and 6 months	Intramuscular
		Adults on pre-dialysis or dialysis or with immunocompromising conditions: 1 mL	Product: Recombivax HB® Dialysis Formulation 3 doses at 0, 1, and 6 months	Intramuscular
	Heplisav-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]	Adults 18 years and older: 0.5 mL	2 doses at 0 and 1 month	Intramuscular
Combination Hepatitis A & Hepatitis B Vaccine	Twinrix® [Combined Hepatitis A (Inactivated) and Hepatitis B Vaccine (Recombinant)]	Adults 19 years and older: 1 mL	Standard Timing: 3 doses at 0,1, and 6 months	Intramuscular
			Accelerated Timing due to anticipated travel: 4 doses at 0 days, 7 days, 21 days, and 12 months	

• **Notes:**

- It is generally recommended that the vaccine series be completed by the same manufacturer for all doses.
- For a 3-dose series of Engerix-B® or Recombivax HB®, the minimum dosing intervals are 4 weeks between dose 1 and dose 2, 8 weeks between dose 2 and dose 3, and 16 weeks between dose 1 and dose 3.
- For a 3-dose series of Twinrix®, the minimum dosing interval is 4 weeks between dose 1 and dose 2 and then

- 5 months between dose 2 and dose 3.
- PreHevbrio™ is a three-antigen Hepatitis B vaccine that was approved for adults 18 years and older in a 3-dose series. However, PreHevbrio™ was withdrawn from the U.S. market in late 2024 due to the manufacturer's bankruptcy. All doses of PreHevbrio™ that were previously administered are considered valid. If a patient is mid-series after receiving a PreHevbrio™ vaccine, they can complete the Hepatitis B vaccine with any other age-appropriate product.
 - If completing the series with Engerix-B® or Recombivax HB®, follow the dosing intervals for a 3-dose Hepatitis B vaccine series.
 - If completing the series with two doses of Heplisav-B® after a single dose of PreHevbrio™, the minimum interval between the two Heplisav-B doses is 4 weeks.
- CDC Hepatitis B Vaccine Recommendations:
 - All adults 19-59 years, including pregnant persons*, should receive the Hepatitis B vaccine series.
 - Adults ≥ 60 years, with known risk factors^ for Hepatitis B, should receive the Hepatitis B vaccine series.
 - Any adult ≥ 60 years who requests Hepatitis B vaccination should receive the Hepatitis B vaccine series.
 - Adults ≥ 60 years, without known risk factors^ for Hepatitis B, may receive the Hepatitis B vaccine series, based on shared clinical decision making.
- *Hepatitis B Vaccination in Pregnancy
 - On 9/11/2024, the FDA updated product labeling for Heplisav-B® to include a new indication for use in pregnant persons.
 - When a Hepatitis B vaccination is needed during pregnancy, providers can now use either Engerix-B®, Recombivax HB®, Heplisav-B®, or Twinrix® (if both Hepatitis A and Hepatitis B vaccination are needed).
- ^Risk factors for Hepatitis B virus infection:
 - Chronic liver disease
 - Persons with hepatitis C
 - Cirrhosis
 - Fatty liver disease
 - Alcoholic liver disease
 - Autoimmune hepatitis
 - ALT or AST > 2 x ULN
 - HIV infection
 - Sexual exposure risk
 - Sex partners of Hepatitis B surface antigen (HBsAg)–positive persons
 - Sexually active persons not in mutually monogamous relationships
 - Persons seeking evaluation or treatment for a sexually transmitted infection
 - Men who have sex with men
 - Current or recent injection drug use
 - Percutaneous or mucosal risk for exposure to blood
 - Household contacts of HBsAg–positive persons
 - Residents and staff of facilities for developmentally disabled persons
 - Health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood–contaminated body fluids
 - Persons on maintenance dialysis (including in–center or home hemodialysis and peritoneal dialysis)
 - Persons who are pre-dialysis
 - Patients with diabetes
 - Incarceration
 - Travel in countries with high or intermediate endemic Hepatitis B

- Contraindications and Precautions:
 - Patients should not receive Hepatitis B vaccines if they have a history of severe allergic reaction to a previous dose or to a vaccine component, including yeast.
 - The vial stopper, syringe plunger stopper, and tip cap of Recombivax HB® products do contain dry natural latex rubber, which may cause allergic reactions in patients who are sensitive to latex.
 - The Twinrix® combination Hepatitis A and Hepatitis B vaccine should not be administered to those with a history of severe allergic reaction to a previous dose or to a vaccine component, including neomycin and yeast.
 - Use caution when administering the vaccine to patients with moderate or severe acute illness with or without fever.

- Common Adverse Reactions:
 - Injection site pain
 - Soreness
 - Fatigue/weakness
 - Headache

- Helpful Resource for Clinical Questions:
 - https://www.immunize.org/askexperts/experts_hepb.asp#adult

- References:
 1. Engerix-B [Hepatitis B vaccine (recombinant)] [prescribing information]. Durham, NC: GlaxoSmithKline Biologicals; 2024.
 2. Recombivax HB [Hepatitis B vaccine (recombinant)] [prescribing information]. Rahway, NJ: Merck & CO., Inc.; 2023.
 3. Heplisav-B [Hepatitis B vaccine (recombinant), Adjuvanted] [prescribing information]. Emeryville, CA: Dynavax; 2024.
 4. PreHevbrio [Hepatitis B vaccine (recombinant)] [prescribing information]. Cambridge, MA: VBI Vaccines; 2021.
 5. Heplisav-B [Hepatitis B vaccine (recombinant), Adjuvanted] [prescribing information]. Emeryville, CA: Dynavax; 2024.
 6. Twinrix [Combined Hepatitis A (inactivated) and Hepatitis B Vaccine (Recombinant)]. [prescribing information]. Mississauga, Ontario: GlaxoSmithKline; 2023.
 7. Sandul AL, Rapposelli K, Nyendak M, Kim M. Updated Recommendation for Universal Hepatitis B Vaccination in Adults Aged 19–59 Years — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:1106. DOI: <http://dx.doi.org/10.15585/mmwr.mm7348a3>.
 8. Centers for Disease Control and Prevention. [Recommended Adult Immunization Schedule for ages 19 years or older] [2025]. [<https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html>]. Accessed [April 5, 2025].
 9. Weng MK, Doshani M, Khan MA, et al. Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:477-488. <http://dx.doi.org/10.15585/mmwr.mm7113a1>.
 10. Immunize.org. Hepatitis B: Ask the Experts. Updated January 17, 2025. Accessed April 5, 2025. <https://www.immunize.org/ask-experts/topic/hepb/>

Published on behalf of the [ASHP Section of Ambulatory Care Practitioners Advisory Group on Ambulatory Care Pharmacotherapy](#).

Reference last updated on 4/16/2025 by:

Amy Mahlum, PharmD, BCACP
Ambulatory Pharmacy Clinical Coordinator
PGY1 Community-Based Pharmacy Residency Program Director
Aurora Health Care – Advocate Health
Milwaukee, WI

Reference updated based on original work by the following individuals:

Tumi Osunsanmi, PharmD
PGY2 Ambulatory Care Pharmacy Resident
The University of Kansas Health System
Kansas City, KS

Libby Stabler, PharmD
PGY2 Ambulatory Care Pharmacy Resident
Mercy Health St. Rita's Medication Management Clinics
Lima, OH

Kristi Kelley, PharmD, BCPS, BCACP, CDCES, BC-ADM
Clinical Professor/Pharmacist
Auburn University Harrison College of Pharmacy
Baptist Health Foundation for Surgical and Medical Care
Birmingham, AL